Skip to main content
The Cochrane Database of Systematic Reviews logoLink to The Cochrane Database of Systematic Reviews
. 2025 Jun 3;2025(6):CD015669. doi: 10.1002/14651858.CD015669

Exercise interventions for the treatment of lower limb lymphoedema after treatment for gynaecological cancers

Takashi Mimura 1,✉, Takeshi Hasegawa 2, Yoshiyuki Okada 3, Tomomi Matsushita 4, Hisashi Noma 5, Erika Ota 6, Edward Barroga 7, Noyuri Yamaji 2
Editor: Cochrane Central Editorial Service
PMCID: PMC12131295  PMID: 40459001

Objectives

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the benefits and harms of load exercise therapy with complex decongestive therapy compared with complex decongestive therapy alone for lower limb lymphoedema after gynaecological cancer treatment.

Background

Description of the condition

Lymphoedema occurs when there is an imbalance between the production and transfer of interstitial fluid, leading to the accumulation of fluid and other substances in the tissue spaces. This condition is caused by a dysfunction or impairment of the lymphatic system, which disrupts normal lymph flow. Specifically, it occurs as a result of congenital abnormalities in the lymphatic system or injury to lymph vessels or nodes, or both (International Society of Lymphology 2003). People with chronic lymphoedema may develop substantial amounts of subcutaneous adipose tissue. The growth of adipocytes may account for the failure of conservative treatment to fully reduce oedema and restore the affected area to its normal size.

Lymphatic vessels originate from lymphatic capillaries in the skin, which merge to form aggregated lymphatic ducts. These pull further into superficial lymphatic vessels that flow above the fascia, and deep lymphatic vessels that pass through multiple lymph nodes to reach deeper layers. These vessels converge into the lymphatic trunks, further upstream. Subsequently, lymphatic trunks from the lower body and the upper left half of the body drain into the thoracic duct, whereas lymphatic trunks from the upper right half of the body flow into the right lymphatic duct. Both eventually empty into the veins via the left and right angulus venosus (Kampmeier 1958).

Lymphatic vessels are equipped with valves to prevent backflow, ensuring that lymph flows anterogradely from the peripheral lymph toward the central lymph (toward the heart (Schmid‐Schonbein 1990)). Smooth muscle cells in the collecting lymphatic vessels also facilitate lymph transport through spontaneous contractions (Ohhashi 2005). However, this flow is quite weak and prone to stagnation, particularly in peripheral areas, such as the lower limbs, which can lead to oedema. To assist this circulation, external factors, such as skin and muscle stimulation on the body surface, and respiratory movements, play an essential role in promoting lymph flow through passive contraction (Kawai 2015). Despite these mechanisms, lymphatic circulation remains very slow, taking approximately half a day to circulate through the body.

Lower limb lymphoedema (LLL) is caused by disorders in the capillary system between the veins and the lymphatic vessels (Partsch 2014). LLL is divided into primary and secondary forms. Primary lymphoedema is thought to result from abnormalities in the development or function (or both) of the lymphatic system, and may occur alone or as part of a syndrome at birth, or later in life (Brouillard 2021). Primary lymphoedema is classified into syndromic, generalised lymphatic dysplasia, congenital‐onset lymphoedema, and late‐onset lymphoedema. The St. George’s classification algorithm is used to accurately diagnose lymphatic disorders (Gordon 2020). Secondary lymphoedema is thought to be caused by infections, trauma, or cancer treatments (cancer‐related lymphoedema (CRLE)). In secondary lymphoedema, the prevalence of lymphatic filariasis (the most common cause) and CRLE alone represent a large global rate. CRLE is most commonly associated with therapeutics for lymph nodes (e.g. lymphadenectomy, irradiation, chemotherapy, or a combination (Rockson 2008)). LLL is more likely to be aggravated than upper limb lymphoedema (ULL), owing to the lower limb’s dependent position. Lymphoedema causes difficulty walking, which makes people less active and weakens their leg muscles, worsening LLL (Aggithaya 2015). CRLE after gynaecological cancer treatment is a disease that impairs quality of life because of motor deterioration of the limbs, body habit changes, and decreased social activities. It also causes significant psychological distress, as it is never completely cured (Goncalves 2010).

Gynaecological cancers are often treated with surgery, including lymph node dissection or biopsy; radiotherapy to the regional lymph nodes; chemotherapy; or a combination (Tada 2009). There has been a reduction in the rates of lymph node dissection for gynaecological cancers in the past 10 to 15 years, with the introduction of sentinel lymph node biopsy techniques for vulvar, cervical, and endometrial cancer (Balaya 2022), and evidence of harm from lymph node dissection for ovarian and endometrial cancer treatment (Frost 2017; Harter 2019). For surgical treatment of gynaecological cancer, the reported risk factors for the development of LLL include dissection of pelvic and para‐aortic lymph nodes, and removal of more than 31 lymph nodes (Kuroda 2017; Todo 2010). Thus, the removal of more lymphatic channels is one of the risk factors. Radiotherapy‐induced lymphoedema is due to pathological changes, such as radiation necrosis and granulation of soft tissues around small lymph vessels, lymph nodes, and blood vessels, and fibrosis due to damage to normal tissue in the irradiated area (Wang 2012). In a study of women treated for cervical cancer with a 4.5‐year follow‐up period, the incidence of severe lymphoedema was reported as 3.4% with pelvic lymph node dissection, 9.5% following pelvic radiation therapy without surgery, and 51.1% for lymph node dissection combined with radiation therapy (Nakamura 2017). The risk of developing lymphoedema is not low with radiotherapy alone, and it significantly increases when radiotherapy is combined with lymph node dissection, chemotherapy, or both (Hayes 2017; Nakamura 2017). Gynaecological chemotherapy is taxane‐based, which also increases the risk of lymphoedema (Nguyen 2017). Within 10 years, CRLE occurs in 20% to 60% of women treated for gynaecologic cancer (Carlson 2020; Kuroda 2017).

As mentioned previously, lymphoedema has a negative impact on people’s well‐being, which, in turn, reduces their overall health‐related quality of life (HRQoL). Notably, 39 HRQoL measurement tools have been used to quantify the effects of lymphoedema on people, and to assess lymphoedema treatment efficacy. The breakdown is as follows: 16 general health (e.g. EuroQoL‐5 dimensions (EQ‐5D ((Devoogdt 2011))), 11 disease‐specific (e.g. European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ (Fayers 2002))), Functional Assessment of Cancer Therapy (FACT), and 12 lymphoedema‐specific questionnaires (Cella 1993). The EQ‐5D, EORTC QLQ, and FACT are very common HRQoL measurement tools, but are not specific to lymphoedema. Only five of 12 lymphoedema‐specific questionnaires have been used for LLL (Lim 2022). Of these five, a quality of life measure for limb lymphoedema (LYMQOL) has been used in most studies, and correlates with the EORTC QLQ‐C30 (Keeley 2010). Women with gynaecological cancer are frequently asked to use the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) to assess their lymphoedema symptoms. The GCLQ is a 20‐item symptom assessment tool designed for gynaecological lymphoedema. The GCLQ score is the sum of the woman’s self‐reported symptom scores for seven groups of symptoms: heaviness (item 14); swelling, general (items 8, 9, 20); swelling, limb (items 18, 19); infection‐related (items 10, 11, 13); numbness (items 7, 12, 15, 16); and physical functioning (items 1 to 6 (Carter 2010)).

Most people with LLL can be easily diagnosed by their clinical history and physical examination. If the diagnosis of LLL is unclear, it is common to first rule out venous diseases (i.e. deep venous thrombosis) with ultrasound examination, and then diagnose LLL with lymphoscintigraphy, using isotopes. All people with LLL are classified according to the staging of lymphoedema by the International Society of Lymphology (ISL), which is divided into four stages, from 0 to 3 (Executive Committee 2016; Table 1). People above stage 1 require LLL treatment.

1. Table 1: Staging of lymphoedema by the International Society of Lymphology.

Stage 0 A subclinical state during which swelling is not evident despite impairments in lymph transport (for months or years before oedema becomes evident)
Stage Ⅰ Early‐onset lymphoedema, marked by an accumulation of protein‐rich tissue fluid that subsides with elevation of the affected limb
Stage Ⅱ An increase in limb swelling that does not subside with elevation of the affected limb
Stage Ⅲ The limb has more fibrotic tissue and non‐pitting oedema, and swells. The skin changes include thickening, hyperpigmentation, deeper skin folds, fat deposits, and warty overgrowths.

Description of the intervention

LLL therapy is based on meticulous skin care and hygiene, moderate activities, and medical education in weight management, insect bite prevention, and sun protection. In addition, almost all people with LLL require conservative and operative therapies.

Conservative therapy is divided into three categories: physical therapy, drug therapy, and psychosocial rehabilitation. Physical therapy mainly consists of complex decongestive therapy (CDT), compression garments alone, massage alone, intermittent pneumatic compression, thermal therapy, and elevation of the affected leg. The ISL identifies CDT as the best conservative therapy. CDT consists of skin care, compression (e.g. low‐stretch bandages), and soft manual massage (manual lymphatic drainage (MLD)) of the affected leg, systematic exercise (intensive phase and maintenance phase), and self‐managed exercises integrated into daily routines, such as walking, stretching, and simple leg movements, at home. Failure of CDT to reduce LLL requires operative therapy for CRLE. The drug therapy for CRLE is rarely reported to be effective, and psychosocial rehabilitation is part of cancer treatment (Executive Committee 2016).

Operative therapy consists of microsurgical procedures, vascularised lymph node transplantation, liposuction, and surgical resection. Surgical resection and liposuction are commonly used worldwide as operative procedures for reducing the volume of CRLE, but microsurgical procedures are becoming more widespread. The most common operative procedure is lymphatic‐venous anastomosis (LVA). LVA is a technique for connecting dilated lymph vessels to nearby veins, thus, redirecting excess lymph fluid into the venous system (Executive Committee 2016). However, CRLE cannot be cured by operative therapy alone. It requires ongoing CDT (Markkula 2019).

In the past, after cancer treatment, people were often instructed not to exercise, particularly not to overuse the affected limb, because of a concern that exercise therapy may increase adverse events, such as infection, fluid retention, or haematoma. However, since the 2000s, the efficacy of exercise therapy for CRLE has been reported (Brown 2013; Sagen 2009). The efficacy of high‐intensity exercises (e.g. anaerobic and aerobic exercises: bench press, dumbbell press, leg press, cycle ergometer, indoor track) has also been reported (Ahmed 2006; Chan 2010; Schmitz 2010).

People with lymphoedema have a decreased range of joint motion, muscle weakness, and pain in the affected limb. Thus, it is important to perform high‐intensity exercises under the guidance of lymphoedema specialists (Executive Committee 2016). The high‐intensity exercises in CDT are one of the physical therapies, and are relatively new interventions. Such therapy is variously called 'intensive phase', 'active exercise with CDT', or 'a complex rehabilitation program and CDT' (Executive Committee 2016). We describe these exercises as load exercise therapy (LET) in this review.

How the intervention might work

Load exercise therapy (LET) with complex decongestive therapy (CDT) reduces lower limb swelling by stimulating the function of the remaining peripheral lymphatic channel, promoting the development of collateral lymphatic pathways, and decongesting impaired lymphatic routes (Morgan 2005). In breast CRLE, there are reports that load exercises relieved lymphoedema, improved symptoms, and augmented muscle strength (Kim 2010; Schmitz 2009). In people with LLL, LET with CDT can improve physical function, allowing them to walk for longer periods of time and participate in more active exercises, resulting in a better quality of life. LET for LLL associated with CRLE is safe, and improves physical function, as shown in a single‐centre cohort study (Katz 2010).

Surgical treatments (mainly LVA) may be used for severe lymphoedema that does not respond to conservative treatment. LVA involves microvascular anastomosis of small lymphatic vessels with small veins in the limb, using advanced plastic surgery techniques. This procedure helps drain excess lymphatic fluid intravenously, resulting in an improvement in lymphoedema. However, it is important to note that LVA is not available worldwide, and is expensive, because of the high level of expertise and surgical time required. Furthermore, to maximise its benefits, LVA must be performed in conjunction with excellent non‐surgical management procedures, such as compression therapy, skin care, and exercise, as it is not a cure‐all solution (Carl 2017).

Therefore, CDT is necessary, with or without surgical treatment. This suggests that LET with CDT can help people improve more, both physically and mentally. This intervention has generally been conducted in healthcare facilities to maintain equity, although there is insufficient consideration of vulnerable or disadvantaged groups, the elderly population, and rural communities, which are unable to visit these healthcare facilities for economic or geographical reasons. However, as the intervention does not require special equipment, one could expect it to be effective for participants in these groups.

Why it is important to do this review

CRLE is mostly reported in women after treatment for breast and gynaecological cancers. The pathogenesis of CRLE after treatment for breast and gynaecological cancers is the same, as it is caused by treatment of the respective regional lymph nodes.

Postoperative LET with CDT for women with breast cancer does not increase surgical complications, but reduces the incidence of ULL, as shown in randomised controlled trials (RCTs) and systematic reviews (Kim 2010; Paramanandam 2014; Schmitz 2009). LET with CDT has been used for ULL after breast cancer treatment (McNeely 2010). Most recommendations are based on studies of ULL following breast cancer treatment, with limited research on LLL after gynaecological cancer treatment.

Several RCTs investigating the efficacy of LET with CDT in women with LLL after gynaecological cancer treatment have started globally. The community is waiting for the results. However, to the best of our knowledge, there is no systematic review of LET with CDT for LLL after gynaecological cancer treatment, and there is currently no consensus about its effectiveness.

Because there are fewer women with LLL associated with CRLE than those with ULL associated with CRLE, LET with CDT for LLL has received less attention (Rockson 2019). Thus, there is a need for more systematic reviews, as LET with CDT for LLL is a clinical question that affects the quality of life of gynaecological cancer survivors (Addis 2009).

Objectives

To assess the benefits and harms of load exercise therapy with complex decongestive therapy compared with complex decongestive therapy alone for lower limb lymphoedema after gynaecological cancer treatment.

Methods

Criteria for considering studies for this review

Types of studies

We will include randomised controlled trials (RCTs), in which participants are randomly assigned to either an intervention group or a control group. RCTs help minimise bias and ensure that any observed differences in outcomes can be attributed to the interventions. We will include results from parallel RCTs, factorial RCTs, cross‐over RCTs, cluster‐RCTs, and quasi‐RCTs (some form of non‐random allocation is used, such as alternate assignment, by day of the week, by the week, or by participant preference) that evaluate the benefits of load exercise therapy (LET) with complex decongestive therapy (CDT) for lower limb lymphoedema (LLL) after gynaecological cancer treatment. We will exclude case reports, cross‐sectional studies, case‐control analyses, and one‐arm trials.

  1. Parallel RCTs: a design in which participants are allocated to different treatment groups, with each group receiving a different intervention simultaneously (e.g. weight training with CDT versus CDT alone; a bicycle ergometer with CDT versus CDT alone)

  2. Factorial RCTs: a design that simultaneously assesses the effects of multiple interventions or factors, allocating participants to different combinations of interventions and evaluating both individual and combined effects (e.g. rehabilitation program with CDT versus CDT alone; effects of interventions with and without radiotherapy)

  3. Cross‐over RCTs: a design in which participants receive multiple interventions in a specific order, with ‘wash‐out’ periods between each intervention to minimise carry‐over effects

  4. Cluster‐RCTs: a design that helps to account for potential contamination with groups (clusters) by allocating groups rather than individual participants to different interventions

  5. Quasi‐RCTs: a design that attempts to balance groups as much as possible to reduce bias when strict randomisation is difficult

Types of participants

Inclusion criteria

We will include adult women over the age of 18 years, with stage Ⅱ or higher LLL that did not improve spontaneously, and who require CDT after gynaecological cancer treatment (gynaecologic cancer is the only primary, including vulvar cancer, and excluding double or metastatic cancer). Clinical history and physical examination are sufficient for making a definitive diagnosis of lymphoedema; lymphoscintigraphy is not necessary. We will include women regardless of ethnicity, cancer site, cancer histology, cancer stage, and type of cancer treatment received. We will include women who receive an intervention beginning before, during, or after cancer treatment. We will include studies if more than 80% of the participants are eligible.

Exclusion criteria

We will exclude women with recurrent cancer and other systemic diseases (arterial insufficiency, deep vein thrombosis, chronic venous insufficiency, cardiac or renal disease, musculoskeletal disease, and neurological disorders). We will also exclude women with skin disorders, such as scarring, inflammation, and infection.

Types of interventions

We will focus on short‐term (within three months) intervention studies targeting LLL after gynaecological cancer treatment. The main comparison of interest is between therapeutic exercise therapies combined with CDT and CDT alone. The therapeutic exercise therapies may include one or more of the following, but we will exclude interventions without CDT.

Group‐based, supervised exercises
  1. Range of motion exercises (including strengthening and resistance exercises): defined as exercises to relax the muscles of the lower legs, with two to three sets of 10 to 20 repetitions per set

  2. Aerobic exercises, using bicycle ergometers, treadmills, and other equipment: 15 to 30 minutes a day of moderate‐to‐high intensity exercises that increase the heart rate

  3. Pool exercises: about one hour of range of motion exercises and aerobic exercises in a swimming pool once a week

  4. Hospital‐based exercises or home‐based exercises

Individual‐based, non‐supervised exercises
  1. Common aerobic exercises integrated into daily routines (e.g. walking, swimming, stretching exercises)

  2. Other physical activities: self‐directed exercises, unrelated to the interventions, to maintain fitness (e.g. walking and stretching)

  3. Hospital‐based exercises or home‐based exercises

We will clearly document and analyse the combination of multiple types of exercise in a single intervention regimen, in our effort to determine whether exercise combined with CDT is better than CDT alone.

Types of outcome measures

We will include clinical outcomes, such as changes in the participants’ lymphoedema and quality of life (QoL). We will also include adverse events caused by LET with CDT. We will assess the outcome measures immediately after interventions (primary time point), at one month, and within three years following the interventions. The measurement of outcome measures will not form part of the inclusion/exclusion criteria. We will assess the benefits of LET with CDT on the following outcomes.

Primary outcomes
  1. Lower limb volume: the change rate in lower limb volume before and after LET with CDT, measured using objective measuring tools (i.e. perometer (Pero‐System, Germany (cm3)), water displacement methods (mL), bioimpedance measurements (kHz), approximation formula for lower limb volume (cm3)

  2. Change in global health‐related quality of life (HRQoL): the change rates in HRQoL scores, using validated tools, such as EORTC QLQ‐C30, FACT‐G, and LYMQOL, measured before and after LET with CDT

  3. Adverse events (AEs): inability to continue the intervention for physical or mental health reasons (e.g. cellulitis, depression, refusal of therapy)

Secondary outcomes
  1. Physical activity: the rate of physical activity, measured before and after LET with CDT

  2. General symptoms: symptoms of LLL, measured before and after LET with CDT, using self‐reported, validated tools (i.e. EORTC QLC‐C30, GCLQ)

  3. Skin condition from LLL: measured before and after LET with CDT; categorised as soft: 0, slightly hard: 1, moderately hard: 2, or severely hard (fibrosis), based on the physical therapist’s assessment in each study

  4. Social functioning: using validated tools (i.e. EORTC QLQ‐C30), measured before and after LET with CDT

  5. Degree of active range of motion of the lower limb: measured before and after LET with CDT

  6. Physical functioning: using validated tools (i.e. EORTC QLQ‐C30), measured before and after LET with CDT

  7. Emotional morbidity: using validated tools (i.e. EORTC QLQ‐C30), measured before and after LET with CDT

We will prioritise the measurement of lower limb volume with a perimeter, if the study includes more than one scale for measuring the lower limb volume. Similarly, if multiple HRQoL instruments are included, we will prioritise GCLQ as the first choice, followed by EORTC QLQ‐C30 as the second choice. We will use dichotomous outcomes for skin condition from LLL, lower limb swelling, and AEs, and continuous outcomes for the other measures.

Search methods for identification of studies

Cochrane Information Specialists will execute a search for all studies, regardless of country, language, and publication status (i.e. published, unpublished, or ongoing). The search strategies for each database will be based on the search designed for MEDLINE. We will use the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE, the sensitivity‐maximizing version (2008 revision); PubMed format (Appendix 1; Lefebvre 2024). We will contact the study authors if additional information is needed.

Electronic searches

We will search the following electronic databases:

  1. Cochrane Central Register of Controlled Trials (CENTRAL; latest issue) in the Cochrane Library;

  2. MEDLINE EBSCO (1946 to present);

  3. Embase Ovid (1980 to present):

  4. PEDro (Physiotherapy Evidence Database; 1999 to present);

  5. LILACS (Latin American and Caribbean Health Sciences Literature; 1982 to present).

We will also search online abstracts of the following international meetings in the past 10 years:

  1. Annual Meeting of the American Society of Clinical Oncology (ASCO)

  2. Annual Meeting of the European Society of Medical Oncology (ESMO)

  3. International Gynecologic Cancer Society (IGCS) Global Meeting.

We will search these trial registers for ongoing trials.

  1. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (http://clinicaltrials.gov/ct2/home; current date)

  2. International Clinical Trials Registry Platform Search Portal (ICTRP; http://www.who.int/clinical-trials-registry-platform/the-ictrp-search-portal; current date)

Searching other resources

We will review the reference lists of included studies and relevant identified systematic reviews to identify potentially eligible studies.

To ensure the inclusion of accurate and reliable data, we will actively identify post‐publication amendments (e.g. expressions of concern, errata, corrigenda, and retractions) for included or eligible studies. This will involve screening retraction databases, such as Retraction Watch (http://retractiondatabase.org/), and checking for updates in journals and databases used for our searches. If necessary, we will contact the study authors for clarification or additional unpublished data. All search strategies, including a list of the sources screened, and the studies reviewed, will be documented in the appendices.

Data collection and analysis

Selection of studies

We will download all titles and abstracts retrieved by electronic searching to the reference management software, EndNote (EndNote 2023). After the duplicates are removed, three review authors (TM, TM, and YO) will independently screen the titles and abstracts for potentially qualified studies, and will independently assess the full‐text reports for eligibility. A fourth review author will carry out the final reviews in the event of disagreements.

We will also process any information from ongoing studies. We will outline the study selection process in a PRISMA flow diagram (Moher 2009).

Data extraction and management

Three review authors (TM, TM, and YO) will independently extract data from eligible studies into a standardised data form, using Covidence (Covidence). We will identify the characteristics of the studies, and prepare a characteristics of included studies table. In the event of disagreements, a third review author will make the decision after consultation with the review authors.

We will extract the following data.

  1. Study information

    1. Author, year of publication, title, country (including papers published in languages other than English)

    2. Funding sources and study authors’ declarations of interest

  2. Eligibility criteria: reason(s) for inclusion and exclusion

  3. Study methods

    1. Study design: randomised trials (i.e. parallel, factorial, cross‐over, cluster‐, and quasi‐)

    2. Study population: number of participants, characteristics of participants (i.e. age, body mass index (BMI), cancer type, history of gynaecological cancer treatment, and lymphoedema staging)

    3. Intervention details: intervention components (single or multiple exercises and exercise description); duration, interval, and intensity of intervention; follow‐up time

    4. Control groups: no LET with usual care (e.g. skin care, compression, and soft manual massage (MLD) for the affected leg, daily life exercise, or combination)

  4. Outcomes

    1. Primary outcome(s)

    2. Secondary outcome(s)

    3. Period between end of intervention and outcome measurement

    4. Type of analysis (e.g. intent‐to‐treat)

Assessment of risk of bias in included studies

Since we are interested in the effect of intervention, we will focus on the ‘effect of assignment’. Two review authors (TM and TM) will independently assess the eligible studies for risk of bias using the Cochrane RoB 2 tool, and the Excel spreadsheet to implement RoB 2 (available from https://www.riskofbias.info/ (Higgins 2024b)). We will assess the seven outcomes included in our summary of findings table, measured at three time points (immediately, one month, and one year after intervention). In the event of disagreements, a third review author will make the decision after consultation with the review authors.

However, the ‘effect of adherence’ may be greater depending on the participant, as it is necessarily carried out in medical facilities, and cases of deviation or non‐adherence are expected to be difficult to identify. In such cases, we will note them as ‘deviations from the intended interventions’.

We will assess the following domains in each study for risk of bias.

  1. Bias arising from the randomisation process

  2. Bias due to deviations from intended interventions

  3. Bias due to missing outcome data

  4. Bias in measurement of the outcome

  5. Bias in selection of the reported result

  6. Overall risk of bias

We will answer the signalling questions for each domain as yes; probably yes; probably no; no; no information, and judge each source of bias based on the signalling questions as low risk of bias, some concerns of bias, and high risk of bias (Sterne 2019). We will provide a citation from the study report together with our judgement in the table for risk of bias.

We will consider the risk of bias assessment in cross‐over RCTs and cluster‐RCTs separately, as these trial designs have specific characteristics. For cross‐over RCTs, we will confirm whether there are washout periods between intervention phases, to assess for possible carry‐over effects. If the washout period is not adequately described or is not sufficiently long, we will only assess the first intervention. For cluster‐RCTs, we will confirm that the characteristics of the participants in each cluster are similar, that imbalance is considered, and that any potential contamination to which participants are exposed in different interventions within the same cluster, is carefully controlled.

Measures of treatment effect

We will use mean differences (MDs) and the ratio of means (RoMs), including 95% confidence intervals (CIs) for continuous outcome data on the same scale. Otherwise, we will use standardised mean differences (SMDs), including 95% CIs. For dichotomous outcome data, we will use risk ratios (RRs) including 95% CIs. We will select intent‐to‐treat data.

Unit of analysis issues

We will consider the impact on our analyses of any non‐standard design variations of the included studies as per Chapter 23 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2024a).

If participants are not individually randomised to one of two intervention groups, we will identify the unit of analysis as follows:

Cross‐over studies

The main problems associated with cross‐over studies are carry‐over effects and period effects. If neither carry‐over effects nor period effects are a problem, we will analyse continuous data from a two‐period, two‐intervention study, using a paired t‐test. We will evaluate the value of ‘measurement on experimental intervention’ minus ‘measurement on control intervention’ separately for each participant, as described in Chapter 23 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2024a).

If carry‐over is a problem, or if a cross‐over design is considered inappropriate for other reasons, we will include only data from the first period (Qizilbash 1998). If imputing missing data is preferable to excluding cross‐over studies from our analysis, we will attempt to approximate a paired analysis by imputing missing standard deviations. We will consult with a statistician (HN) about cross‐over studies with dichotomous outcomes.

Cluster studies

We will extract the following data, and analyse them using a summary measurement from each cluster, as described in Chapter 23 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2024a).

  1. The number of clusters (or groups) randomised to each intervention group and the total number of participants in the study, or the average (mean) size of each cluster

  2. The outcome data, ignoring the cluster for the total number of individuals (e.g. the number or proportion of individuals with events, or means and standard deviations for continuous data)

  3. An estimate of the intracluster (or intraclass) correlation coefficient (ICC)

If the ICC estimates are not reported, we will use external estimates obtained from similar studies. To address potential uncertainty introduced by borrowing ICC estimates, we will conduct sensitivity analyses to evaluate the impact of carrying ICC values on the results, as described in Chapter 23 (section 1.6) of the Cochrane Handbook for Systematic Reviews of Interventions. Specifically, we will use the ICC to estimate the relative variability within and between clusters and assess how these variations affect the robustness of our findings (Higgins 2024a).

Studies with multiple intervention groups

We will adjust these studies to overcome unit‐of‐analysis errors for a study that may contribute to multiple correlation comparisons.

  1. We will combine each similar intervention group to create a single pair‐wise comparison.

  2. We will select one pair of interventions and exclude the others.

Dealing with missing data

We will handle missing data in accordance with Chapter 10 of the Cochrane Handbook for Systematic Reviews of Interventions (Deeks 2024).

  1. Whenever possible, we will contact the original academic researchers to request disclosure of missing data.

  2. If we are unable to obtain the missing data, we will replace the missing data with mean values and predictive values from a regression analysis.

  3. We will conduct sensitivity analysis to assess whether the assumptions are reasonable, if the data from the eligible reports are dubious.

Assessment of heterogeneity

We will consider how consistent the results of the included studies are, and create a summary table for the clinical and methodological characteristics in the studies. If the CIs for the results have poor overlap, we will assess the statistical heterogeneity using forest plots and the Chi2 test to determine whether observed differences in the results are compatible with chance alone. We will use the I2 statistic for quantifying inconsistency.

Assessment of reporting biases

Whenever possible, we will search for unreported results in the included studies, and work to minimise unreported bias, as outlined in Chapter 13 of the Cochrane Handbook for Systematic Reviews of Interventions (Eyding 2010).

If at least 10 studies provide data for an outcome, we will create funnel plots to assess the risk of reporting biases, and assess the risk of small‐study effects using tests for funnel plot asymmetry (Sterne 2001).

Data synthesis

We will pool the data from all the included studies for meta‐analysis. If the clinical and methodological heterogeneity of each study is almost the same, we will use an inverse‐variance method for continuous data or a Mantel‐Haenszel method for dichotomous data (Mantel 1959). We will use a random‐effects model to adjust for statistical heterogeneity in different studies if the heterogeneity of each study is small (DerSimonian 1986). We will also conduct sensitivity analyses to explore the impact of including studies with a higher risk of bias. If quantitative meta‐analysis is not appropriate, we will integrate data from the included study results using the Synthesis Without Meta‐analysis (SWiM) reporting guideline (https://training.cochrane.org/online-learning/cochrane-methodology/swim-reporting-guideline). We will perform analysis using Review Manager (RevMan (RevMan 2025)).

Subgroup analysis and investigation of heterogeneity

If there are more than 10 studies included in this review, we will perform subgroup analyses according to the following categories:

  1. type of cancer (e.g. ovarian cancer versus endometrial cancer versus uterine cervical cancer)

  2. type of cancer treatments (e.g. regional lymph node excision versus radiation therapy ± lymph node excision, chemotherapy (taxane therapy) versus radiation therapy)

If the treatment is mixed, we will categorise the main treatment for the regional lymph node as the type of cancer treatment:

  1. stage of lymphoedema (e.g. stage Ⅰ versus stage Ⅱ)

  2. age (e.g. younger than 65 years versus 65 years and older)

Several control conditions are involved in this systematic review. Thus, we will assess the effects of potential heterogeneity of the differences amongst the control conditions by performing subgroup analyses that adopt a different control condition (e.g. CDT, routine nursing care, or compression therapy). If the treatment of the control conditions is not clear, we will contact the study author(s) to request the treatment of the controls.

We will utilise the formal test for subgroup differences in RevMan to assess the heterogeneity between subgroups (RevMan 2025). This technique will ensure that any subgroup analyses conducted in our review are statistically supported, enhancing the reliability and validity of our results.

Sensitivity analysis

We will assess the impact of sensitivity analysis on the overall estimates of treatment effects and the heterogeneity measures. If we observe remarkable changes, we will delve into specific reasons for these changes and discuss how these sources impact the overall outcomes.

To assess the influences of the studies with a high overall risk of bias, we will undertake sensitivity analyses for the primary outcomes, which exclude the studies with a high risk of bias.

Summary of findings and assessment of the certainty of the evidence

We will develop a summary of findings table for the comparison, therapeutic exercise therapies combined with CDT versus CDT alone, and present the results for these outcomes.

  1. Lower limb volume

  2. Change in global HRQoL

  3. Adverse events (AEs)

  4. Physical activity

  5. General symptoms of LLL, measured before and after LET with CDT, using self‐reported, validated tools

  6. Skin condition from LLL before and after LET with CDT

  7. Social functioning, using validated tools, before and after LET with CDT.

We will include results of lower limb volume measured with a perometer if the study includes more than one scale for measuring the lower limb volume. Similarly, if multiple HRQoL instruments are included, we will prioritise GCLQ as the first choice, followed by EORTC QLQ‐C30 as the second choice. We will use dichotomous outcomes for skin condition from LLL, lower limb swelling, and AEs, and continuous outcomes for the other measures.

We will assess the outcome measures within three months after the interventions, and prioritise outcomes in studies immediately after the interventions to ascertain the direct impact of the intervention.

Two review authors (TM and TM) will independently judge the certainty of evidence using the GRADE approach. In the event of disagreements, a third review author (TH) will make the decision after consultation with the review authors.

We will use GRADEpro GDT online software to assess and present the certainty of evidence for each outcome (GRADEpro GDT). We will assess the certainty of evidence by assessing the overall risk of bias, consistency of effect, imprecision, indirectness, and publication bias for each outcome. The overall RoB 2 judgement for each included outcome will feed into the GRADE assessment. We will provide reasons for downgrading the certainty of evidence in the footnotes and add explanations to help readers understand the results, as needed.

Acknowledgements

Editorial and peer‐reviewer contributions

We acknowledge the important editorial and reviewer contributions of the experts regarding our article. The following people conducted the editorial process.

  • Sign‐off Editor (final editorial decision): Jo Morrison, Department of Gynaecological Oncology, Taunton, Somerset

  • Managing Editor (selected peer reviewers, provided editorial guidance to the authors, edited the article): Sam Hinsley, Cochrane Central Editorial Service

  • Editorial Assistant (conducted editorial policy checks, collated peer‐reviewer comments and supported the editorial team): Leticia Rodrigues, Cochrane Central Editorial Service

  • Copy Editor (copy editing and production): Victoria Pennick, Cochrane Central Production Service

  • Peer‐reviewers (provided comments and recommended an editorial decision): Nuala Livingstone, Cochrane Evidence Production and Methods Directorate (methods); Jo Platt, Central Editorial Information Specialist (search); Dr. Stephane Vignes, MD, Department of Lymphology, Cognacq‐Jay Hospital, Paris (clinical); Laura Gilchrist, PT, PhD, St. Catherine University, St. Paul MN, USA (clinical); and Aditi Bauskar, Independent Consultant (consumer).

Appendices

Appendix 1. Search strategy for MEDLINE in EBSCO

S1 MH "Genital Neoplasms, Female+"
S2 TI ((gynae* OR gyne* OR ovar* OR uter* OR fallopian* OR vulva* OR endometr* OR vagina* OR cervi* OR endocervi*) N5 (neoplas* OR tumor* OR tumour* OR cancer* OR carcinoma* OR malignan* OR adenocarcinoma* OR sarcoma*))
S3 AB ((gynae* OR gyne* OR ovar* OR uter* OR fallopian* OR vulva* OR endometr* OR vagina* OR cervi* OR endocervi*) N5 (neoplas* OR tumor* OR tumour* OR cancer* OR carcinoma* OR malignan* OR adenocarcinoma* OR sarcoma*))
S4 TI (((genital*) AND (female* OR woman* OR women* OR mother* OR girl*)) N5 (neoplas* OR tumor* OR tumour* OR cancer* OR carcinoma* OR malignan* OR adenocarcinoma* OR sarcoma*)))
S5 AB (((genital*) AND (female* OR woman* OR women* OR mother* OR girl*)) N5 (neoplas* OR tumor* OR tumour* OR cancer* OR carcinoma* OR malignan* OR adenocarcinoma* OR sarcoma*)))
S6 S1 OR S2 OR S3 OR S4 OR S5
S7 MH "Lymphedema+"
S8 MH "Edema" AND MH "Lower Extremity+"
S9 TX (lymphedem* OR "lymph edem*" OR lymphoedem* OR "lympho edem*")
S10 TX (((lower AND (limb? OR extremit*)) OR leg?) N2 (edema* OR oedema*))
S11 S7 OR S8 OR S9 OR S10
S12 S6 AND S11
S13 MH "Compression Bandages+"
S14 TI (compress*) OR AB (compress*)
S15 TI (elastic) OR AB (elastic)
S16 TI (bandag*) OR AB (bandag*)
S17 TI (wrap*) OR AB (wrap*)
S18 TI (stocking*) OR AB (stocking*)
S19 TI (garment*) OR AB (garment*)
S20 TI (decongestive) OR AB (decongestive)
S21 TI (AECT) OR AB (AECT)
S22 TI (CDT) OR AB (CDT)
S23 TI (CDP) OR AB (CDP)
S24 TI (CPT) OR AB (CPT)
S25 TI (KPE) OR AB (KPE)
S26 MH "Exercise+"
S27 TI (exercis*) OR AB (exercis*)
S28 TI (training*) OR AB (training*)
S29 TI (kinesither* OR kinesi‐ther*) OR AB (kinesither* OR kinesi‐ther*)
S30 TI (aerobic*) OR AB (aerobic*)
S31 TI (ergometer* OR ergo‐meter*) OR AB (ergometer* OR ergo‐meter*)
S32 TI (treadmill* OR tread‐mill* OR running‐machine*) OR AB (treadmill* OR tread‐mill* OR running‐machine*)
S33 MH "Aquatic Therapy"
S34 TI (aquatic*) OR AB (aquatic*)
S35 TI (pool‐ther* OR pool‐treat*) OR AB (pool‐ther* OR pool‐treat*)
S36 MH "Hydrotherapy"
S37 TI (hydrother* OR hydro‐ther* OR hydrotreat*OR hydro‐treat*) OR AB (hydrother* OR hydro‐ther* OR hydrotreat*OR hydro‐treat*)
S38 TI (ai‐chi* OR tai‐chi) OR AB (ai‐chi* OR tai‐chi)
S39 TI (walking* OR ambulation* OR gait OR gaits OR locomot*) OR AB (walking* OR ambulation* OR gait OR gaits OR locomot*)
S40 TI (stretching*) OR AB (stretching*)
S41 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40
S42 S12 AND S41
S43 PT "Controlled Clinical Trial"
S44 PT "Randomized Controlled Trial"
S45 TI (randomized OR randomised) OR AB (randomized OR randomised)
S46 TI placebo* OR AB placebo*
S47 MH "Clinical Trials as Topic"
S48 TI randomly OR AB randomly
S49 TI trial
S50 S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49
S51 MH (Animals+ NOT Humans)
S52 S50 NOT S51
S53 S42 AND S52

Contributions of authors

All authors substantially contributed to the study design.

Takeshi Hasegawa (TH) is the principal investigator. 
Takashi Mimura (TM) and TH designed and provided an overview of the protocol. 
TM, Tomomi Matsushita (TM), and Yoshiyuki Okada (YO) will be responsible for study selection and data extraction during the review process. 
Eriko Ota (EO) and Hisashi Noma (HN) provided expert methodological and statistical input into the protocol and proposed the statistical analysis. 
TM, TH, TM, YO, HM, EO, and Edward Barroga (EB) reviewed the protocol draft, checked the content, made critically important intellectual content revisions, and approved the final report.

EB also proofread the whole systematic review in English. 
All review authors will review and approve the final report. 
The systematic review revisions will be drafted by TM and TH, and the revised systematic review will be checked by all authors (TM, TH, TM, YO, HM, EO, and EB). 
Selection of studies and data extraction will be undertaken by TM, TM, YO, and TH. 
Data analysis and interpretation will be undertaken by TM, TM, YO, EO, HN, and TH. 
Review write‐up, textual data accuracy, and interpretations will be rechecked by EB, and revisions for critically important textual content will be undertaken by EB. 
Review updates will be undertaken by TM, TM, YO, and TH.

Sources of support

Internal sources

  • Showa University Research Adiministration Center (SURAC) , Japan

    This work was undertaken as part of a program (Showa University Next Leaders in Study and Education: SUNLiSE) organized by SURAC.

External sources

  • JSPS KAKENHI, Japan

    This work was supported by JSPS KAKENHI Grant Number 19K03092.

Declarations of interest

TM: nothing to declare

TH: nothing to declare

TM: nothing to declare

YO: nothing to declare

HN: received a research fund from GlaxoSmithKline and consulting fees from Kyowa Kirin, GlaxoSmithKline, Ono Pharmaceutical, Sony, and Terumo, outside the submitted work

EO: nothing to declare

EB: nothing to declare

New

References

Additional references

Addis 2009

  1. Armer AD, Billinham J, Brorson R, Campisi H, Damstra C, Daroczy RJ, et al. Best Practice for the Management of Lymphoedema: An International Consensus. Medicak Education Partnership (MEP) Ltd, London, 15 October 2009. Available from https://woundsinternational.com/consensus-documents/best-practice-for-the-management-of-lymphoedema-an-international-consensus/.

Aggithaya 2015

  1. Aggithaya MG, Narahari SR, Ryan TJ. Yoga for correction of lymphedema's impairment of gait as an adjunct to lymphatic drainage: a pilot observational study. International Journal of Yoga 2015;8(1):54-61. [DOI: 10.4103/0973-6131.146063] [DOI] [PMC free article] [PubMed] [Google Scholar]

Ahmed 2006

  1. Ahmed RL, Thomas W, Yee D, Schmitz KH. Randomized controlled trial of weight training and lymphedema in breast cancer survivors. Journal of Clinical Oncology 2006;24(18):2765-72. [DOI: 10.1200/JCO.2005.03.6749] [DOI] [PubMed] [Google Scholar]

Balaya 2022

  1. Balaya V, Guani B, Morice P, Querleu D, Fourchotte V, Leblanc E, et al. Long-term oncological safety of sentinel lymph node biopsy in early-stage cervical cancer: a post-hoc analysis of SENTICOL I and SENTICOL II cohorts. Gynecologic Oncology 2022;164(1):53-61. [DOI: 10.1016/j.ygyno.2021.10.074] [DOI] [PubMed] [Google Scholar]

Brouillard 2021

  1. Brouillard P, Witte MH, Erickson RP, Damstra RJ, Becker C, Quéré I, et al. Primary lymphoedema. Nature Reviews. Disease Primers 2021;7(1):77. [DOI: 10.1038/s41572-021-00309-7] [DOI] [PubMed] [Google Scholar]

Brown 2013

  1. Brown JC, John GM, Segal S, Chu CS, Schmitz KH. Physical activity and lower limb lymphedema among uterine cancer survivors. Medicine and Science in Sports and Exercise 2013;45(11):2091-7. [DOI: 10.1249/MSS.0b013e318299afd4] [DOI] [PMC free article] [PubMed] [Google Scholar]

Carl 2017

  1. Carl HM, Walia G, Bello R, Clarke-Pearson E, Hassanein AH, Cho B, et al. Systematic review of the surgical treatment of extremity lymphedema. Journal of Reconstructive Microsurgery 2017;33(6):412-25. [DOI: 10.1055/s-0037-1599100] [DOI] [PubMed] [Google Scholar]

Carlson 2020

  1. Carlson JW, Kauderer J, Hutson A, Carter J, Armer J, Lockwood S, et al. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients. Gynecologic Oncology 2020;156(2):467-74. [DOI: 10.1016/j.ygyno.2019.10.009] [DOI] [PMC free article] [PubMed] [Google Scholar]

Carter 2010

  1. Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecologic Oncology 2010;117(2):317-23. [DOI: 10.1016/j.ygyno.2010.01.022] [DOI] [PMC free article] [PubMed] [Google Scholar]

Cella 1993

  1. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. Journal of Clinical Oncology 1993;11(3):570-9. [DOI: 10.1200/JCO.1993.11.3.570] [DOI] [PubMed] [Google Scholar]

Chan 2010

  1. Chan DN, Lui LY, So WK. Effectiveness of exercise programmes on shoulder mobility and lymphoedema after axillary lymph node dissection for breast cancer: systematic review. Journal of Advanced Nursing 2010;66(9):1902-14. [DOI: 10.1111/j.1365-2648.2010.05374.x] [DOI] [PubMed] [Google Scholar]

Covidence [Computer program]

  1. Covidence. Version 15 January 2025. Melbourune, Australia: Veritas Health Innovation, 2025. Available at https://www.covidence.org.

Deeks 2024

  1. Deeks JJ, Higgins JPT, Altman DG, McKenzie JE, Veroniki AA, editor(s). Chapter 10: Chapter 10: Analysing data and undertaking meta-analyses (last updated November 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.

DerSimonian 1986

  1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88. [DOI: 10.1016/0197-2456(86)90046-2] [DOI] [PubMed] [Google Scholar]

Devoogdt 2011

  1. Devoogdt N, Van Kampen M, Geraerts I, Coremans T, Christiaens MR. Lymphoedema Functioning, Disability and Health questionnaire (Lymph-ICF): reliability and validity. Physical Therapy 2011;91(6):944-57. [DOI: 10.2522/ptj.20100087] [DOI] [PubMed] [Google Scholar]

EndNote 2023 [Computer program]

  1. EndNote. The EndNote Team, Version EndNote 21. Philadelphia, PA, USA: Clarivate Analytics, May 2023. Available at www.endnote.com.

Executive Committee 2016

  1. Executive Committee. The diagnosis and treatment of peripheral lymphedema: 2016 consensus document of the International Society of Lymphology. Lymphology 2016;49(4):170-84. [PubMed] [Google Scholar]

Eyding 2010

  1. Eyding D, Lelgemann M, Grouven U, Harter M, Kromp M, Kaiser T, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737. [DOI: 10.1136/bmj.c4737] [DOI] [PMC free article] [PubMed] [Google Scholar]

Fayers 2002

  1. Fayers P, Bottomley A, Group Eortc Quality of Life, Quality of Life Unit. Quality of life research within the EORTC—the EORTC QLQ-C30. European organisation for research and treatment of cancer. European Journal of Cancer 2002;38(Suppl 4):S125-33. [DOI: 10.1016/s0959-8049(01)00448-8] [DOI] [PubMed] [Google Scholar]

Frost 2017

  1. Frost JA, Webster KE, Bryant A, Morrison J. Lymphadenectomy for the management of endometrial cancer. Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No: CD007585. [DOI: 10.1002/14651858.CD007585.pub4] [DOI] [PMC free article] [PubMed] [Google Scholar]

Goncalves 2010

  1. Goncalves V. Long-term quality of life in gynecological cancer survivors. Current Opinion in Obstetrics & Gynecology 2010;22(1):30-5. [DOI: 10.1097/GCO.0b013e328332e626] [DOI] [PubMed] [Google Scholar]

Gordon 2020

  1. Gordon K, Varney R, Keeley V, Riches K, Jeffery S, Van Zanten M, et al. Update and audit of the St George's classification algorithm of primary lymphatic anomalies: a clinical and molecular approach to diagnosis. Journal of Medical Genetics 2020;57(10):653-9. [DOI: 10.1136/jmedgenet-2019-106084] [DOI] [PMC free article] [PubMed] [Google Scholar]

GRADEpro GDT  [Computer program]

  1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), 2025. Available at http://www.gradepro.org.

Harter 2019

  1. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. New England Journal of Medicine 2019;380(9):822-32. [DOI: 10.1056/NEJMoa1808424] [DOI] [PubMed] [Google Scholar]

Hayes 2017

  1. Hayes SC, Janda M, Ward LC, Reul-Hirche H, Steele ML, Carter J, et al. Lymphedema following gynecological cancer: results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors. Gynecologic Oncology 2017;146(3):623-9. [DOI: 10.1016/j.ygyno.2017.06.004] [DOI] [PubMed] [Google Scholar]

Higgins 2024a

  1. Higgins JPT, Eldridge S, Li T. Chapter 23: Including variants on randomized trials (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook.

Higgins 2024b

  1. Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ,et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024. Available from www.training.cochrane.org/handbook 2022.

International Society of Lymphology 2003

  1. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema. Consensus document of the International Society of Lymphology. Lymphology 2003;36(2):84-91. [PubMed] [Google Scholar]

Kampmeier 1958

  1. Kampmeier OF. On the lymphatic system of Ascaphus; its evolutionary significance. Anatomical Record 1958;132(3):343-63. [DOI: 10.1002/ar.1091320309] [DOI] [PubMed] [Google Scholar]

Katz 2010

  1. Katz E, Dugan NL, Cohn JC, Chu C, Smith RG, Schmitz KH. Weight lifting in patients with lower-extremity lymphedema secondary to cancer: a pilot and feasibility study. Archives of Physical Medicine and Rehabilitation 2010;91(7):1070-6. [DOI: 10.1016/j.apmr.2010.03.021] [DOI] [PMC free article] [PubMed] [Google Scholar]

Kawai 2015

  1. Kawai Y, Ajima K, Nagai T, Yokoyama Y, Kaidoh M, Seto E, et al. Abdominal respiration induces hemodilution and related reduction in ADH concentration of blood. Lymphatic Research and Biology 2015;13(3):202-7. [DOI: 10.1089/lrb.2015.0017] [DOI] [PubMed] [Google Scholar]

Keeley 2010

  1. Keeley V, Crooks S, Locke J, Veigas D, Riches K, Hilliam R. A quality of life measure for lmb lymphoedema (LYMQOL). Journal of Lymphoedema 2010;5:26-37. [Google Scholar]

Kim 2010

  1. Kim DS, Sim YJ, Jeong HJ, Kim GC. Effect of active resistive exercise on breast cancer-related lymphedema: a randomized controlled trial. Archives of Physical Medicine and Rehabilitation 2010;91(12):1844-8. [DOI: 10.1016/j.apmr.2010.09.008] [DOI] [PubMed] [Google Scholar]

Kuroda 2017

  1. Kuroda K, Yamamoto Y, Yanagisawa M, Kawata A, Akiba N, Suzuki K, et al. Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study. BMC Women's Health 2017;17(1):50. [DOI: 10.1186/s12905-017-0403-1] [DOI] [PMC free article] [PubMed] [Google Scholar]

Lefebvre 2024

  1. Lefebvre C, Glanville J, Briscoe S, Featherstone R, Littlewood A, Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies [last updated March 2025]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5.1. Cochrane, 2025. Available from www.training.cochrane.org/handbook.

Lim 2022

  1. Lim P, Li H, Neoh D, Ng SK. Health-related quality of life measurement tools for lymphedema: a review of the literature. Plastic and Reconstructive Surgery, Global Open 2022;10(4):e4276. [DOI: 10.1097/GOX.0000000000004276] [DOI] [PMC free article] [PubMed] [Google Scholar]

Mantel 1959

  1. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48. [PubMed] [Google Scholar]

Markkula 2019

  1. Markkula SP, Leung N, Allen VB, Furniss D. Surgical interventions for the prevention or treatment of lymphoedema after breast cancer treatment. Cochrane Database of Systematic Reviews 2019, Issue 2. Art. No: CD011433. [DOI: 10.1002/14651858.CD011433.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]

McNeely 2010

  1. McNeely ML, Campbell K, Ospina M, Rowe BH, Dabbs K, Klassen TP, et al. Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane Database of Systematic Reviews 2010, Issue 6. Art. No: CD005211. [DOI: 10.1002/14651858.CD005211.pub2] [DOI] [PMC free article] [PubMed] [Google Scholar]

Moher 2009

  1. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097] [DOI] [PMC free article] [PubMed] [Google Scholar]

Morgan 2005

  1. Morgan PA, Moody M, Franks PJ, Moffatt CJ, Doherty DC. Assessing community nurses' level of knowledge of lymphoedema. British Journal of Nursing 2005;14(1):8-13. [DOI: 10.12968/bjon.2005.14.1.17365] [DOI] [PubMed] [Google Scholar]

Nakamura 2017

  1. Nakamura K, Masuyama H, Ida N, Haruma T, Kusumoto T, Seki N, et al. Radical hysterectomy plus concurrent chemoradiation/radiation therapy is negatively associated with return to work in patients with cervical cancer. International Journal of Gynecological Cancer 2017;27(1):117-22. [DOI: 10.1097/IGC.0000000000000840] [DOI] [PubMed] [Google Scholar]

Nguyen 2017

  1. Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Annals of Surgical Oncology 2017;24(10):2972-80. [DOI: 10.1245/s10434-017-5960-x] [DOI] [PMC free article] [PubMed] [Google Scholar]

Ohhashi 2005

  1. Ohhashi T, Mizuno R, Ikomi F, Kawai Y. Current topics of physiology and pharmacology in the lymphatic system. Pharmacology & Therapeutics 2005;105(2):165-88. [DOI: 10.1016/j.pharmthera.2004.10.009] [DOI] [PubMed] [Google Scholar]

Paramanandam 2014

  1. Paramanandam VS, Roberts D. Weight training is not harmful for women with breast cancer-related lymphoedema: a systematic review. Journal of Physiotherapy 2014;60(3):136-43. [DOI: 10.1016/j.jphys.2014.07.001] [DOI] [PubMed] [Google Scholar]

Partsch 2014

  1. Partsch H, Lee B. Phlebology and lymphology—a family affair. Phlebology 2014;29(10):645-7. [DOI: 10.1177/0268355514551514] [DOI] [PubMed] [Google Scholar]

Qizilbash 1998

  1. Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M, Dementia Trialists' Collaboration. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA 1998;280(20):1777-82. [DOI: 10.1001/jama.280.20.1777] [DOI] [PubMed] [Google Scholar]

RevMan 2025 [Computer program]

  1. Review Manager (RevMan). Version 8.20. The Cochrane Collaboration, 2025. Available at revman.cochrane.org.

Rockson 2008

  1. Rockson SG, Rivera KK. Estimating the population burden of lymphedema. Annals of the New York Academy of Sciences 2008;1131:147-54. [DOI: 10.1196/annals.1413.014] [DOI] [PubMed] [Google Scholar]

Rockson 2019

  1. Rockson SG, Keeley V, Kilbreath S, Szuba A, Towers A. Cancer-associated secondary lymphoedema. Nature Reviews. Disease Primers 2019;5(1):22. [DOI: 10.1038/s41572-019-0072-5] [DOI] [PubMed] [Google Scholar]

Sagen 2009

  1. Sagen A, Karesen R, Risberg MA. Physical activity for the affected limb and arm lymphedema after breast cancer surgery. A prospective, randomized controlled trial with two years follow-up. Acta Oncologica 2009;48(8):1102-10. [DOI: 10.3109/02841860903061683] [DOI] [PubMed] [Google Scholar]

Schmid‐Schonbein 1990

  1. Schmid-Schonbein GW. Microlymphatics and lymph flow. Physiological Reviews 1990;70(4):987-1028. [DOI: 10.1152/physrev.1990.70.4.987] [DOI] [PubMed] [Google Scholar]

Schmitz 2009

  1. Schmitz KH, Ahmed RL, Troxel A, Cheville A, Smith R, Lewis-Grant L, et al. Weight lifting in women with breast-cancer-related lymphedema. New England Journal of Medicine 2009;361(7):664-73. [DOI: 10.1056/NEJMoa0810118] [DOI] [PubMed] [Google Scholar]

Schmitz 2010

  1. Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L, Smith Ret al. Weight lifting for women at risk for breast cancer-related lymphedema: a randomized trial. JAMA 2010;304(24):2699-705. [DOI: 10.1001/jama.2010.1837] [DOI] [PubMed] [Google Scholar]

Sterne 2001

  1. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. Journal of Clinical Epidemiology 2001;54(10):1046-55. [DOI: 10.1016/s0895-4356(01)00377-8] [DOI] [PubMed] [Google Scholar]

Sterne 2019

  1. Sterne JA, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. [DOI: 10.1136/bmj.l4898] [DOI] [PubMed] [Google Scholar]

Tada 2009

  1. Tada H, Teramukai S, Fukushima M, Sasaki H. Risk factors for lower limb lymphedema after lymph node dissection in patients with ovarian and uterine carcinoma. BMC Cancer 2009;9:47. [DOI: 10.1186/1471-2407-9-47] [DOI] [PMC free article] [PubMed] [Google Scholar]

Todo 2010

  1. Todo Y, Yamamoto R, Minobe S, Suzuki Y, Takeshi U, Nakatani M, et al. Risk factors for postoperative lower-extremity lymphedema in endometrial cancer survivors who had treatment including lymphadenectomy. Gynecologic Oncology 2010;119(1):60-4. [DOI: 10.1016/j.ygyno.2010.06.018] [DOI] [PubMed] [Google Scholar]

Wang 2012

  1. Wang PL, Cheng YB, Kuerban G. The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer. Journal of Radiation Research 2012;53(1):125-9. [DOI: 10.1269/jrr.11094] [DOI] [PubMed] [Google Scholar]

Articles from The Cochrane Database of Systematic Reviews are provided here courtesy of Wiley

RESOURCES